Nicox Extends Cash Runway into Q4 2025

Press ReleaseNicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance of €0.5 million extends the cash runway into Q4 2025, enabling focus on future growthOngoing discussions and business development outreach underway for          NCX 470 U.S. partnershipTwo NCX 470 clinical readouts in 2025 – Whistler Mechanism of Action in             Q2...

Biot, 06/03/2025 (informazione.news - comunicati stampa - salute e benessere)

 

 

 

1 Programme d'Augmentation de Capital par Exercice d'Options (Capital increase program through exercise of warrants)
2 Non-diluted share capital as of 5 March 2025

3 Taking into account the issue of 37,129,720 new shares issuable at the date of this press release on the exercise of stock options (1,187,205 shares), the vesting of restricted stock (4,078,177 shares), the exercise of warrants (18,664,338 shares) and the conversion of bonds convertible into equity (13,200,000 shares). 

4 The lowest volume-weighted average daily share price, calculated over the 2 consecutive trading sessions preceding each issue.
5 The issue price of the shares must be, within the framework of this resolution, "at least equal to the average of the average volume-weighted prices of the last 3 trading days preceding the setting of the issue price, possibly reduced by a maximum discount of 30%".
6 Share price of €0.30 on March 5, 2025
7 Delegation of a capital increase with cancellation of shareholders' preferential subscription rights to a category of persons with specific characteristics

Attachment